CIMA LABS Announces Collaborative Agreement With Aventis To Develop Allegra(R) Fast-Dissolve Product.Business Editors & Health/Medical Writers EDEN PRAIRIE Eden Prairie A city of eastern Minnesota, a residential suburb of Minneapolis. Population: 57,300. , Minn.--(BUSINESS WIRE)--Sept. 25, 2002 CIMA LABS INC inc - /ink/ increment, i.e. increase by one. Especially used by assembly programmers, as many assembly languages have an "inc" mnemonic. Antonym: dec. . (Nasdaq:CIMA) today announced it has signed a product development and worldwide licensing agreement with Aventis Pharmaceuticals Inc., which conducts the Aventis prescription drugs prescription drug Prescription medication Pharmacology An FDA-approved drug which must, by federal law or regulation, be dispensed only pursuant to a prescription–eg, finished dose form and active ingredients subject to the provisos of the Federal Food, Drug, business in the U.S., to develop a fast-dissolve version of Allegra Al·leg·ra A trademark for the drug fexofenadine hydrochloride. fexofenadine hydrochloride Allegra, Telfast (UK) Pharmacologic class: Peripherally selective piperidine, selective histamine (R) (fexofenadine), one of the leading antihistamines Antihistamines Definition Antihistamines are drugs that block the action of histamine (a compound released in allergic inflammatory reactions) at the H1 on the market today. Under this agreement, CIMA would receive fees and milestone payments for the successful development of a fast-dissolve tablet See digitizer tablet and tablet computer. TABLET - A query language. ["Human Factor Comparison of a Procedural and a Non-procedural Query Language", C. Welty et al, ACM Trans Database Sys 6(4):626-649 (Dec 1981)]. , which incorporates Aventis' active drug ingredient, fexofenadine, with CIMA's OraSolv(R) drug delivery system. CIMA would also receive royalty payments based on Aventis' commercial sales if the product is granted regulatory approval. CIMA and Aventis are currently negotiating a separate manufacturing and supply agreement for the product. As with CIMA's collaborative agreements with other pharmaceutical companies, Aventis will be responsible for marketing and distribution of this product. John M. Siebert, Ph.D., president and chief executive officer, commented: "We are very pleased to be announcing CIMA's third major collaborative agreement in 2002, particularly with a company of Aventis' global stature. Development of a fast-dissolve version of Allegra was a challenging project, and we are proud to have played a key role in this successful product development collaboration. Our new relationship with Aventis follows announcements earlier this year of partnerships with Schering-Plough and Wyeth. We believe our increasingly successful strategy of developing important new fast-dissolve products in collaboration with major pharmaceutical companies is setting the stage for progressively stronger operating results in CIMA's future." About CIMA LABS CIMA develops and manufactures prescription and over-the-counter products based upon its proprietary, fast-dissolve drug delivery technologies, OraSolv(R) and DuraSolv(R). Based on our technologies, an active drug ingredient, which we frequently taste-mask, is formulated into a new, orally disintegrating dosage form A dosage form is the physical form of a dose of medication, such as a capsule or injection. The route of administration is dependent on the dosage form of a given drug. that dissolves quickly in the mouth without chewing chewing or mastication Up-and-down and side-to-side movements of the lower jaw, using the teeth to grind food for easier swallowing. During chewing, the tongue shapes food into a lump and saliva lubricates it for swallowing. or the need for water. CIMA's business involves a dual operating strategy. We develop and manufacture fast-dissolve versions of drugs for pharmaceutical company partners for whom we currently produce three branded prescription pharmaceuticals and two over-the-counter brands. CIMA is also developing proprietary products utilizing our fast-dissolve technologies, as well as our new OraVescent(R) enhanced absorption, transmucosal drug delivery system. The information in this press release, including the information related to CIMA's expectations about product developments and introductions, and sources of future revenues, contain forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. A number of factors could cause actual results to differ materially from CIMA's assumptions and expectations. These factors include the timely and successful completion of product development activities, regulatory approval for the proposed product, and the success of pharmaceutical companies in marketing CIMA's product. Additional factors that may cause actual results to differ from CIMA's assumptions and expectations include those that are set forth under the heading "Factors That Could Affect Future Results," included in CIMA's most recent filings with the Securities and Exchange Commission. All forward-looking statements are qualified by, and should be considered in conjunction with, such cautionary statements. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion